Related Experiment Video
Updated: May 10, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Towards a 'clicked' PSMA targeting gene delivery bioconjugate-polyplex for prostate cancer
Amanda R Noble1, Saeed Akkad1, Nicholas D J Yates1
1Department of Chemistry, University of York Heslington York YO10 5DD UK martin.fascione@york.ac.uk.
Abstract:
Prostate cancer is the most common cancer in men in the UK with over 50 000 new cases diagnosed each year and although therapeutic advances in surgery, anti-androgens, radio- and chemotherapy have increased survival rates, there still remains a need for new treatments to combat the most aggressive forms of the disease. Gene therapy offers promise as an alternative approach but is reliant on selective targeting to the cancer cell surface. Herein we describe the novel construction of a prostate specific membrane antigen (PSMA) binding bioconjugate-polyplex, based on a glutamate-urea peptide scaffold using 'click' chemistry, which we demonstrate is capable of targeted delivery of a GFP gene to PSMA overexpressing prostate cancer cells, and therefore may have potential future application as part of a prostate cancer gene delivery therapy.
Insights
Researchers developed a novel gene therapy delivery system for prostate cancer. This bioconjugate targets prostate specific membrane antigen (PSMA) on cancer cells, showing potential for future gene delivery treatments.
Area of Science:
- Oncology
- Biotechnology
- Gene Therapy
Background:
- Prostate cancer is a leading cancer in UK men, with over 50,000 diagnoses annually.
- Current treatments like surgery, chemotherapy, and radiotherapy have improved survival but aggressive forms remain challenging.
- Gene therapy presents a promising alternative, requiring precise targeting to cancer cell surfaces.
Purpose of the Study:
- To develop a novel gene delivery system for prostate cancer.
- To create a bioconjugate capable of targeting prostate specific membrane antigen (PSMA).
- To assess the potential of this system for future prostate cancer gene therapy.
Main Methods:
- Construction of a prostate specific membrane antigen (PSMA) binding bioconjugate-polyplex.
- Utilized a glutamate-urea peptide scaffold and 'click' chemistry for bioconjugate synthesis.
- Demonstrated targeted delivery of a Green Fluorescent Protein (GFP) gene.
Main Results:
- Successfully constructed a novel bioconjugate-polyplex targeting PSMA.
- Achieved targeted delivery of the GFP gene specifically to PSMA-overexpressing prostate cancer cells.
- The bioconjugate showed high specificity for cancer cells expressing PSMA.
Conclusions:
- The developed bioconjugate-polyplex demonstrates effective targeted gene delivery to PSMA-positive prostate cancer cells.
- This novel system holds potential for future applications in prostate cancer gene therapy.
- Further research may lead to advanced therapeutic strategies for aggressive prostate cancer forms.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers